Summary
Fifteen patients with acute nonlymphocytic leukemia have been randomized for treatment with daunorubicin (1.0–1.5 mg/kg) either as the free drug (for 45 min or 4 h) or as the drug bound to a DNA carrier (for 5–6 h). The correlation between plasma kinetics of daunorubicin and its main metabolite daunorubicinol and the different administration schedules of daunorubicin has been studied by reversed-phase liquid chromatography.
Plasma concentration kinetics of daunorubicin as well as the daunorubicin-DNA complex was biphasic in character. Maximum plasma level of daunorubicin was found during the infusion period. Its concentration decreased rapidly when the infusion stopped and was below the detection limit of the analytical method 2–4 h later. The data suggests a slower disposition of the daunorubicin-DNA complex compared with the free drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersson, B., Beran, M., Eberhardsson, B., Ehrsson, H., Eksborg, S., Slania, P.: Studies on the tissue distribution, in vivo and in vitro bone marrow toxicity of daunorubicin and the daunorubicin-DNA complex (in Swedish). Abstr. HE 9, p. 180. Presented at Läkarsällskapets Riksstämma, Stockholm 1977
Asbell, M. A., Schwartzbach, E., Wodinsky, I., Yesair, D. W.: Metabolism of daunomycin (NSC-82151) in vitro and the chemotherapeutic activity of isolated metabolites in vivo. Cancer Chemother. Rep. [Part 1] 56, 315 (1972)
Benjamin, R. S.: Clinical pharmacology of the anthracycline antibiotics. In: Topics in hematology. Proceedings of the 16th International Congress of Hematology, Kyoto, September 5–11, 1976. Seno, S., Takaku, F., Irino, S. (eds.), p. 1053. Amsterdam, Oxford, Excerpta Medica 1977
Eksborg, S., Ehrsson, H., Andersson, B., Beran, M.: Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. J. Chromatogr. 153, 211 (1978)
Gahrton, G., Björkholm, M., Brenning, G., Christenson, I., Engstedt, L., Franzén, S., Gullbring, B., Holm, G., Högman, C., Hörnsten, P., Jameson, S., Killander, A., Simonsson-Lindemalm, C., Lockner, D., Lönnqvist, B., Mellstedt, H., Palmblad, J., Paul, C., Pauli, C., Peterson, C., Reizenstein, P., Simonsson, B., Skårberg, K.-O., Udén, A.-M., Wadman, B. et al.: Treatment of acute nonlymphocytic leukemia in adults with DNA-daunorubicin complex — a preliminary report. Cancer Chemother. Pharmacol. 2, 73–76 (1979)
Huffman, D. H., Benjamin, R. S., Bachur, N. R.: Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin. Pharmacol. Ther. 13, 895 (1972)
Ohnuma, T., Holland, J. F., Chen, J.-H.: Pharmacological and therapeutic efficacy of daunomycin: DNA complex in mice. Cancer Res. 35, 1767 (1975)
Seeber, S., Schilcher, R. B., Brucksch, K. P., Käding, J., Schmidt, C. G.: Cytostatic efficicacy of DNA-complexes of adriamycin, daunomycin, and actinomycin D. II. Comparative in vivo studies in an Ehrlich-Ascites tumor. Z. Krebsforsch. 90, 307 (1977)
Sokal, G., Trouet, A., Michaux, J. L., Cornu, G.: DNA-daunorubicin complex: Preliminary trials in human leukaemia. Eur. J. Cancer 9, 391 (1973)
Trouet, A., Deprez-de Campeneere, D., Duve, C. de: Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature [New Biol.] 239, 110 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andersson, B., Andersson, I., Beran, M. et al. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother. Pharmacol. 2, 15–17 (1979). https://doi.org/10.1007/BF00253099
Issue Date:
DOI: https://doi.org/10.1007/BF00253099